Clinical Trials

  1. Patients with ischemic non-ischemic cardiomyopathy undergoing LVAD insertion as destination-therapy or bridge to transplant will receive AAV6.SERCA2a one month after VAD placement by percutaneous gene transfer at a dose of 5x1012 drp (8 patients) and saline (8 patients). Weaning protocol 3-6 months after VAD placement. (Harefield/Papworth, UK, R. Hajjar/S. Harding/E. Birks). CAERUS.

  2. Randomized, double-blind, placebo-controlled, sequential dose escalation trial in patients with NYHA Class III/IV HF due to ischemic/non-ischemic cardiomyopathy. Evaluate safety and feasibility of a single antegrade epicardial coronary artery infusion of FOUR Dose levels of AAV1.SERCA2a in 45 patients. (Celladon Corp., M. Jessup & D. Mancini). CUPID.